Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

There exist differences in the epidemiological characteristics, clinicopathological features,
tumor biological characteristics, treatment patterns, and drug selections between gastric …

Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

Background Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the
activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other …

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …

Gastric cancer (GC) is a high-incidence cancer worldwide. Most patients are diagnosed at
an advanced stage, by which time they have limited treatment options and poor prognosis …

Gastric cancer is the fifth most common cancer and the third most common cause of cancer
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …